Handelsavisen
prelaunch
Companies Healthcare QTI.O
QT
QTI.O NASDAQ Healthcare Equipment

QT Imaging Holdings Inc

$2,63
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
31,7M USD
P/E
EV / Rev
Div yield
Op margin
-23,4 %
ROE
-327,1 %
Net margin
-111,4 %
Debt / equity
0,71
Beta
52w range
Volume
Day range
Prev close
$5,00
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

QT Imaging Holdings Inc develops and commercializes advanced medical imaging equipment, primarily serving diagnostic and therapeutic applications in the healthcare sector.

Business. QT Imaging Holdings Inc (QTI.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupHealthcare Equipment
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target11,60

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
11,60
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
-327,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning QTI.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to QTI.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Qt Imaging Holdings Inc (QTI.O) has recorded its first institutional analysis, marking the initial baseline for tracking ownership activity. This inaugural review highlights the emergence of four new notable holders as of March 31, 2026, signaling early institutional interest in the company’s equity. The most significant addition among these new investors holds 19,325 shares, valued at approximately $0.11 million, representing a portfolio weight of roughly 0.0015%. This position stands out as the largest single entry among the newly identified stakeholders, suggesting a focused allocation despite the modest absolute value. Other notable additions include an investor holding 5,556 shares (valued at $0.03 million), another with 3,002 shares (valued at $0.02 million), and a fourth holding 1,594 shares (valued at $0.01 million). Collectively, these four entities now constitute the entirety of the company’s top five holder count, indicating a concentrated but nascent institutional base. With no prior analyst coverage or index membership recorded, these new holdings provide the first tangible data points for assessing market sentiment toward Qt Imaging. The absence of prior delta computation means these positions establish the initial reference frame for future ownership trends and potential liquidity developments.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    QT Imaging Holdings Inc (QTI.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupHealthcare Equipment
    AI synthesis
    GENERATED

    QT Imaging operates with a market capitalization of $84.3 million and a price-to-book ratio of 13.08, indicating a premium valuation relative to its equity base. The company's liquidity position is characterized by a current ratio of 2.81, suggesting adequate short-term liquidity, but its operating cash flow of -$8.96 million and free cash flow of -$21.08 million highlight significant cash outflows. The debt-to-equity ratio of 0.71 reflects a moderate leverage profile, with long-term debt of $4.59 million against total equity of $6.45 million.

    Profitability metrics are underperforming relative to industry norms. The company reported a net loss of $21.08 million and an operating loss of $4.44 million, resulting in a negative return on equity of -3.27% and a return on assets of -0.92%. These figures fall below the typical performance of peers in the Advanced Medical Equipment & Technology industry, which emphasizes high R&D investment and long-term value creation.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare equipment sector, which is sensitive to regulatory and reimbursement changes.

    Looking ahead, the company is projected to face continued financial pressure. Revenue is expected to remain flat or decline in the current fiscal year, with no significant growth anticipated in the next fiscal year. The negative operating and free cash flows suggest a lack of internal funding for expansion or R&D, which is critical in a capital-intensive industry.

    The risk assessment highlights liquidity as a medium concern, with negative net cash after subtracting total debt. While dilution risk is currently low, the company's negative earnings and cash flows could necessitate future equity raises, potentially diluting existing shareholders. No recent filings or transcripts indicate material changes in the company's strategic direction or financial outlook.

    Analysts have assigned a mean price target of $11.60, with a strong buy recommendation, but the absence of buy or hold ratings suggests limited consensus on the company's near-term prospects. The discrepancy between analyst optimism and the company's financial performance warrants close monitoring of upcoming earnings and capital-raising activities.

    Qt Imaging Holdings Inc (QTI.O) has recorded its first institutional analysis, marking the initial baseline for tracking ownership activity. This inaugural review highlights the emergence of four new notable holders as of March 31, 2026, signaling early institutional interest in the company’s equity. The most significant addition among these new investors holds 19,325 shares, valued at approximately $0.11 million, representing a portfolio weight of roughly 0.0015%. This position stands out as the largest single entry among the newly identified stakeholders, suggesting a focused allocation despite the modest absolute value. Other notable additions include an investor holding 5,556 shares (valued at $0.03 million), another with 3,002 shares (valued at $0.02 million), and a fourth holding 1,594 shares (valued at $0.01 million). Collectively, these four entities now constitute the entirety of the company’s top five holder count, indicating a concentrated but nascent institutional base. With no prior analyst coverage or index membership recorded, these new holdings provide the first tangible data points for assessing market sentiment toward Qt Imaging. The absence of prior delta computation means these positions establish the initial reference frame for future ownership trends and potential liquidity developments.

    Key takeaways
    • QT Imaging is trading at a premium to book value despite reporting a net loss and negative cash flows.
    • The company's liquidity position is adequate in the short term but is challenged by ongoing negative operating cash flows.
    • Profitability metrics are significantly below industry norms, with a negative return on equity and assets.
    • Revenue concentration and lack of geographic diversification increase exposure to sector-specific risks.
    • Analysts are optimistic about the stock, but the lack of consensus and financial underperformance suggest caution.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $2,63
    Market cap
    $84.3M
    Enterprise value
    $88.9M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    13.1x
    P / Tangible book
    13.1x
    Tangible book
    $6.4M
    Net cash
    -$4.6M
    Current ratio
    2.8
    Debt / equity
    0.7
    ROA
    -91.6%
    ROE
    -3.3%
    Cash conversion
    42.0%
    CapEx / revenue
    -0.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryHealthcare Equipment10,0B node revenueVEEV 32,0%QDEL 27,4%EVH 18,8%OMCL 11,9%TBRG 3,5%LFMD 1,9%SLP 0,8%SOPH 0,8%Other 3,0%
    Source: company disclosures · own-taxonomy revenue-covered setQTI 0,2% · rank #15 of 24

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs QTI · multiples and returns
    VE
    VEEV
    Veeva Systems Inc
    $158,86
    25,9B USD
    P/E
    157,9x
    vs self
    Div yield
    vs self
    ROE
    3,3 %
    +330,4 vs self
    QD
    QDEL
    QuidelOrtho Corporation
    $17,71
    1,2B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -58,9 %
    +268,2 vs self
    EV
    EVH
    Evolent Health, Inc.
    $3,14
    351,4M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -134,8 %
    +192,3 vs self
    OM
    OMCL
    OMNICELL, INC.
    $46,82
    P/E
    vs self
    Div yield
    vs self
    ROE
    1,7 %
    +328,8 vs self
    TB
    TBRG
    Trubridge Inc
    $26,24
    393,6M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -1,0 %
    +326,1 vs self
    LF
    LFMD
    Lifemd Inc
    $3,73
    177,5M USD
    P/E
    13,6x
    vs self
    Div yield
    vs self
    ROE
    62,0 %
    +389,1 vs self
    SL
    SLP
    SIMULATIONS PLUS, INC.
    $18,31
    370,5M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -46,6 %
    +280,6 vs self
    SO
    SOPH
    Sophia Genetics SA
    $5,80
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,11
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,11
    Revenueno estimateno estimate38,6M USD
    Operating incomeno estimateno estimate340,000 USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy1
    Buy0
    Hold0
    Sell0
    Strong sell0
    12-month price target$11,60 · Median $11,60
    Low $10,00High $13,20
    Operating income · consensus340,000 USD
    EPS surprise
    −1 735,6 %
    reported vs consensus · miss
    Revenue surprise
    −51,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$10,00
    Mean$11,60
    Median$11,60
    High$13,20
    Spot$2,63
    +341.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-23,4 %Above median
    Net Margin-111,4 %Below median
    ROE-327,1 %Bottom quartile
    Capex / Rev-0,7 %Above P75
    D/E0,71Bottom quartile
    Cash Conv0,42Below median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 200 160 sh2 exercises · 7 grants7 insiders
    • Weiner ZeevDirector · Stock Option (right to buy) → Common StockDisposed 8 888 @ $2,25exercise · 2026-03-17
    • Weiner ZeevDirector · Stock Option (right to buy) → Common StockDisposed 14 166 @ $2,00exercise · 2026-03-17
    • Katz Avi SDirector, CHAIRMAN · PRIVATE WARRANT → COMMON STOCKAcquired 48 214 @ $6,43purchase · 2026-01-22
    • Weiner ZeevDirector · Stock Option (right to buy) → Common StockAcquired 25 000 @ $1,90grant · 2025-08-11
    • Taylor RossDirector · Stock Option (right to buy) → Common StockAcquired 25 000 @ $1,90grant · 2025-08-11
    • KLOCK JOHN C JRDirector, 10% owner · Stock Option (right to buy) → Common StockAcquired 25 000 @ $1,90grant · 2025-08-11
    • Katz Avi SDirector, Chairman · Stock Option (right to buy) → Common StockAcquired 25 000 @ $1,90grant · 2025-08-11
    • GREENE JAMES SDirector · Stock Option (right to buy) → Common StockAcquired 25 000 @ $1,90grant · 2025-08-11
    • Dinu RalucaDirector, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 25 000 @ $1,90grant · 2025-08-11
    • DICKSON DANIEL HDirector · Stock Option (right to buy) → Common StockAcquired 25 000 @ $1,90grant · 2025-08-11

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • QT Imaging Holdings Inc Market data — financials · 2026-05-29
    • QT Imaging Holdings Inc Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying1 buys · 0 sellsnet $155K8 insiders · last 365d
    • Katz Avi SDirector, Chairman · Common StockOther 3 500 · 2026-03-20
    • DICKSON DANIEL HDirector · Common StockOther 3 500 · 2026-03-20
    • Weiner ZeevDirector · Common StockOther 3 500 · 2026-03-20
    • GREENE JAMES SDirector · Common StockOther 3 500 · 2026-03-20
    • Jennings Jay WalterChief Financial Officer · Common StockOther 2 800 · 2026-03-20
    • Taylor RossDirector · Common StockOther 3 500 · 2026-03-20
    • KLOCK JOHN C JRDirector, 10% owner · Common StockOther 3 500 · 2026-03-20
    • Dinu RalucaDirector, Chief Executive Officer · Common StockOther 3 500 · 2026-03-20
    • Dinu RalucaDirector, Chief Executive Officer · Common StockOther 500 000 · 2026-03-20
    • Dinu RalucaDirector, Chief Executive Officer · Common StockOther 16 000 · 2026-03-20
    • Weiner ZeevDirector · Common StockOther 8 888 @ $2,25$20K · 2026-03-17
    • Weiner ZeevDirector · Common StockOther 14 166 @ $2,00$28K · 2026-03-17
    • Katz Avi SDirector, CHAIRMAN · COMMON STOCKBought 24 107 @ $6,43$155K · 2026-01-22

    Short positioning

    194.7Kshares short+11.8% vs prior
    13.58days to cover
    39.5%short of daily vol
    385fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    QTI.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00M&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 1.8%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 788.4%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 6.1%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 278.2%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 63.6%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 5.6%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 167.6%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): 225.2%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 361.9%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 10.7%Derived (calculated)
    • Net margin (FY 2025-12-31): -111.4%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 2.57xDerived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 20.5%Derived (calculated)
    • Current ratio (FY 2025-12-31): 2.81xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 40.9%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 287.9%Derived (calculated)
    • Return on equity (FY 2025-12-31): -327.1%Derived (calculated)
    • Return on assets (FY 2025-12-31): -91.6%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -134.6%Derived (calculated)
    • Gross margin (FY 2025-12-31): 45.4%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 5.6%Derived (calculated)
    • Shareholders' equity (annual): USD 6.45MSEC XBRL filing
    • Net income (annual): USD -21.08MSEC XBRL filing
    • Gross profit (annual): USD 8.58MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDER4 institutional position changes flagged
    2026-05-21FILING8-K filing →
    2026-05-15FILING424B5 filing →
    2026-05-13FILING10-Q filing →
    2026-05-13FILING8-K filing →
    2026-03-25FILING8-K filing →
    2026-03-25FILING8-K filing →
    2026-03-25FILING10-K filing →
    2026-03-20 00:00 UTCINSIDER14 insider transactions — 2026-03 2 derivative
    2026-03-20 00:00 UTCINSIDER14 insider transactions — 2026-03 2 derivative
    2026-03-20INSIDERKatz Avi S transacted 3.5k sh — Director, Chairman
    2026-03-20INSIDERDICKSON DANIEL H transacted 3.5k sh — Director
    2026-03-20INSIDERWeiner Zeev transacted 3.5k sh — Director
    2026-03-20INSIDERGREENE JAMES S transacted 3.5k sh — Director
    2026-03-20INSIDERJennings Jay Walter transacted 2.8k sh — Chief Financial Officer
    2026-03-20INSIDERTaylor Ross transacted 3.5k sh — Director
    2026-03-20INSIDERKLOCK JOHN C JR transacted 3.5k sh — Director, 10% owner
    2026-03-20INSIDERDinu Raluca transacted 3.5k sh — Director, Chief Executive Officer
    2026-03-20INSIDERDinu Raluca transacted 500.0k sh — Director, Chief Executive Officer
    2026-03-20INSIDERDinu Raluca transacted 16.0k sh — Director, Chief Executive Officer
    2026-03-17INSIDERWeiner Zeev transacted 8.9k sh — Director ~$20k
    2026-03-17INSIDERWeiner Zeev transacted 14.2k sh — Director ~$28k
    2026-03-17INSIDERWeiner Zeev disposed of 14.2k sh Stock Option (right to buy) — Director
    2026-03-17INSIDERWeiner Zeev disposed of 8.9k sh Stock Option (right to buy) — Director
    2026-02-25FILING8-K filing →
    2026-02-18FILING8-K filing →
    2026-02-06FILING8-K filing →
    2026-01-29FILING424B3 filing →
    2026-01-27FILING8-K filing →
    2026-01-22 00:00 UTCINSIDER2 insider transactions — 2026-01 · net buy $155k 1 derivative
    2026-01-22 00:00 UTCINSIDER2 insider transactions — 2026-01 · net buy $155k 1 derivative
    2026-01-22INSIDERKatz Avi S bought 24.1k sh — Director, CHAIRMAN ~$155k
    2026-01-22INSIDERKatz Avi S acquired 48.2k sh PRIVATE WARRANT — Director, CHAIRMAN
    Showing the 40 most recent of 51 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage